This article estimates the comprehensive value of direct-acting antivirals for the treatment of hepatitis C virus using a generalized cost-effectiveness analysis. Objectives: To estimate the ...

Modeling at 2023 net pricing estimated semaglutide would avert >358,000 cardiovascular events/deaths, saving ~$15B in cardiovascular care plus ~$8B in other care, but adding ~$344B lifetime drug spend ...

Introduction The clinical management of Obstructive Hypertrophic Cardiomyopathy remains challenging, and the phase III EXPLORER-HCM trial has demonstrated that the novel cardiac myosin inhibitor ...

William Padula, PhD, MSc, MS, assistant professor of pharmaceutical and health economics, University of California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, discusses the benefits ...

Cost-Effectiveness of Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Older Patients With High-Risk Myelodysplastic Syndrome: Analysis of BMT CTN 1102 A randomized controlled trial ...

Characterizing Opioid Prescribing Trends of Medical Oncologists From 2013 to 2019: Analysis From the Centers for Medicare & Medicaid Services Medicare Part D Prescribers Database This work supported ...

Analysis of data from a randomized trial finds trabeculectomy typically is the better financial bet than tube shunt surgery as a first option to treat glaucoma.

This commentary argues that practitioners of cost-effectiveness analyses should incorporate dynamic drug pricing into formal cost-effectiveness analyses (CEAs). For reasons we discuss, doing so will ...

As an epidemiologist and physician, I’ve long been concerned about how health interventions for marginalized communities are evaluated. A new study explores that concern and offers some solutions for ...

A certain type of bariatric surgery may prove more cost-effective over time than a popular weight loss drug, an economic evaluation study suggested. In an analysis of adults with class II obesity (BMI ...